Indian Regulators Halt Sun Pharma's Ophthalmic Product Manufacturing Due to Quality Deficiencies

Indian drug regulators have ordered Sun Pharmaceutical Industries, the country's largest pharmaceutical company, to cease manufacturing, selling, and distributing ophthalmic products from its Assam facility. This action follows the identification of significant deficiencies in the company's quality management system during a joint inspection by central and state drug regulators. The directive means Sun Pharma cannot restart ophthalmic drug production at the plant until regulators review and accept its compliance report. This regulatory action comes after Sun Pharma voluntarily recalled approximately 11 eye-care brands and all ophthalmic products from the facility in July as a precautionary measure.